Long-Acting Muscarinic Antagonists Under Investigational to Treat Chronic Obstructive Pulmonary Disease

References

• Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2020. Available from: https://goldcopd.org/wp-content/uploads/2019/12/GOLD-2020-FINAL-ver1.2-03Dec19_WMV.pdf. Accessed November 25, 2020.
   Google Scholar
• Canning BJ. Reflex regulation of airway smooth muscle tone. J Appl Physiol. 2006;101(3):971–985. doi:10.1152/japplphysiol.00313.2006
   PubMed Web of Science ®Google Scholar
• Cazzola M, Page CP, Calzetta L, et al. Pharmacology and therapeutics of bronchodilators. Pharmacol Rev. 2012;64:450–504.
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Muscarinic receptor subtypes in airways. Life Sci. 1993;52(5–6):521–527. doi:10.1016/0024-3205(93)90310-Y
   Web of Science ®Google Scholar
• Brodde OE, Michel MC. Adrenergic and muscarinic receptors in the human heart. Pharmacol Rev. 1999;51:651–690.
   PubMed Web of Science ®Google Scholar
• Calzetta L, Rogliani P, Ora J, et al. LABA/LAMA combination in COPD: a meta-analysis on the duration of treatment. Eur Respir Rev. 2017;26:160043.
   Web of Science ®Google Scholar
• Calzetta L, Matera MG, Cazzola M. Pharmacological mechanisms leading to synergy in fixed-dose dual bronchodilator therapy. Curr Opin Pharmacol. 2018;40:95–103. doi:10.1016/j.coph.2018.03.011
   PubMed Web of Science ®Google Scholar
• Heusler P, Cussac D, Naline E, et al. Characterization of V0162, a new long-acting antagonist at human M3 muscarinic acetylcholine receptors. Pharmacol Res. 2015;100:117–126. doi:10.1016/j.phrs.2015.07.033
   PubMed Web of Science ®Google Scholar
• Devillier P, Garrigue E, D’Auzers G, et al. V0162 a new long-acting bronchodilator for treatment of chronic obstructive lung diseases: preclinical and clinical results. Respir Res. 2015;16(1):68. doi:10.1186/s12931-015-0227-1
   PubMed Web of Science ®Google Scholar
• Theravance Biopharma. Theravance biopharma and mylan receive FDA approval for YUPELRITM (revefenacin) in adults with chronic obstructive pulmonary disease [media release]. November 9, 2018. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210598Orig1s000Approv.pdf. Accessed November 25, 2020.
   Google Scholar
• Hegde SS, Pulido-Rios MT, Luttmann MA, et al. Pharmacological properties of revefenacin (TD-4208), a novel, nebulized long-acting, and lung selective muscarinic antagonist, at human recombinant muscarinic receptors and in rat, guinea pig, and human isolated airway tissues. Pharmacol Res Perspect. 2018;6(3):e00400. doi:10.1002/prp2.400
   PubMed Web of Science ®Google Scholar
• Pulido-Rios MT, McNamara A, Obedencio GP, et al. In vivo pharmacological characterization of TD-4208, a novel lung-selective inhaled muscarinic antagonist with sustained bronchoprotective effect in experimental animal models. J Pharmacol Exp Ther. 2013;346(2):241–250. doi:10.1124/jpet.113.203554
   PubMed Web of Science ®Google Scholar
• Heo Y-A. Revefenacin: first global approval. Drugs. 2019;79(1):85–91. doi:10.1007/s40265-018-1036-x
   PubMed Web of Science ®Google Scholar
• Borin MT, Lo A, Barnes CN, et al. Pharmacokinetics and safety of revefenacin in subjects with impaired renal or hepatic function. Int J Chron Obstruct Pulmon Dis. 2019;14:2305–2318. doi:10.2147/COPD.S203709
   PubMed Web of Science ®Google Scholar
• Donohue J, Feldman G, Sethi S, et al. Cardiovascular safety of revefenacin for nebulization: a review of randomized controlled trial data. Chest. 2018;154(4):734A–735A. doi:10.1016/j.chest.2018.08.664
   Web of Science ®Google Scholar
• Borin MT, Barnes CN, Darpo B, et al. Revefenacin, a long-acting muscarinic antagonist, does not prolong QT interval in healthy subjects: results of a placebo- and positive-controlled thorough QT Study. Clin Pharmacol Drug Dev. 2020;9:130–139.
   Web of Science ®Google Scholar
• Quinn D, Barnes CN, Yates W, et al. Pharmacodynamics, pharmacokinetics and safety of revefenacin (TD-4208), a long-acting muscarinic antagonist, in patients with chronic obstructive pulmonary disease (COPD): results of two randomized, double-blind, Phase 2 studies. Pulm Pharmacol Ther. 2018;48:71–79. doi:10.1016/j.pupt.2017.10.003
   PubMed Web of Science ®Google Scholar
• Pudi KK, Barnes CN, Moran EJ, et al. A 28-day, randomized, double-blind, placebo-controlled, parallel group study of nebulized revefenacin in patients with chronic obstructive pulmonary disease. Respir Res. 2017;18(1):182. doi:10.1186/s12931-017-0647-1
   PubMed Web of Science ®Google Scholar
• Donohue JF, Kerwin E, Barnes CN, et al. Efficacy of revefenacin, a long-acting muscarinic antagonist for nebulized therapy, in patients with markers of more severe COPD: a post hoc subgroup analysis. BMC Pulm Med. 2020;20(1):134. doi:10.1186/s12890-020-1156-4
   Web of Science ®Google Scholar
• Siler TM, Moran EJ, Barnes CN, et al. Safety and efficacy of revefenacin and formoterol in sequence and combination via a standard jet nebulizer in patients with chronic obstructive pulmonary disease: a phase 3b, randomized, 42-Day Study. Chronic Obstr Pulm Dis. 2020;7:99–106.
   Web of Science ®Google Scholar
• Cazzola M, Page C, Matera MG. Long-acting muscarinic receptor antagonists for the treatment of respiratory disease. Pulm Pharmacol Ther. 2013;26(3):307–317. doi:10.1016/j.pupt.2012.12.006
   PubMed Web of Science ®Google Scholar
• Villetti G, Pastore F, Bergamaschi M, et al. Bronchodilator activity of (3R)-3-[[[(3-fluorophenyl)[(3,4,5-trifluorophenyl)methyl]amino] carbonyl]oxy]-1-[2-oxo-2-(2-thienyl)ethyl]-1-azoniabicyclo[2.2.2]octane bromide (CHF5407), a potent, long-acting, and selective muscarinic M3 Receptor antagonist. J Pharmacol Exp Ther. 2010;335(3):622–635. doi:10.1124/jpet.110.170035
   PubMed Web of Science ®Google Scholar
• Jiang J-X, Cao R, Deng W-D, et al. Characterization of bencycloquidium bromide, a novel muscarinic M3 receptor antagonist in guinea pig airways. Eur J Pharmacol. 2011;655(1–3):74–82. doi:10.1016/j.ejphar.2011.01.017
   Web of Science ®Google Scholar
• Cao R, Dong X-W, Jiang J-X, et al. M3 muscarinic receptor antagonist bencycloquidium bromide attenuates allergic airway inflammation, hyperresponsiveness and remodeling in mice. Eur J Pharmacol. 2011;655(1–3):83–90. doi:10.1016/j.ejphar.2011.01.024
   PubMed Web of Science ®Google Scholar
• Sun L, Ding L, Wang Y, et al. Pharmacokinetics, safety and tolerability of bencycloquidium bromide, a novel selective muscarinic M1/M3 receptor antagonist, after single and multiple intranasal doses in healthy Chinese subjects: an open-label, single-center, first-in-Human Study. Drugs R D. 2012;12(1):17–28. doi:10.2165/11599330-000000000-00000
   PubMedGoogle Scholar
• Jiang Z, Xiao H, Liu S, et al. Bencycloquidium bromide nasal spray is effective and safe for persistent allergic rhinitis: a phase III, multicenter, randomized, double-blinded, placebo-controlled clinical trial. Eur Arch Otorhinolaryngol. 2020;277(11):3067–3077. doi:10.1007/s00405-020-06183-5
   Web of Science ®Google Scholar
• Zhang S-J, Jiang J-X, Ren -Q-Q, et al. Effects of the inhalation of the M3 receptor antagonist bencycloquidium bromide in a mouse cigarette smoke-induced airway inflammation model. Drug Dev Res. 2015;76(3):123–131. doi:10.1002/ddr.21248
   PubMed Web of Science ®Google Scholar
• Cazzola M, Rogliani P, Segreti A, et al. An update on bronchodilators in phase I and II clinical trials. Expert Opin Investig Drugs. 2012;21(10):1489–1501. doi:10.1517/13543784.2012.710602
   PubMed Web of Science ®Google Scholar
• Jorup C, Bengtsson T, Strandgården K, et al. Transient paradoxical bronchospasm associated with inhalation of the LAMA AZD9164: analysis of two phase I, randomised, double-blind, placebo-controlled studies. BMC Pulm Med. 2014;14(1):52. doi:10.1186/1471-2466-14-52
   Web of Science ®Google Scholar
• Mete A, Bowers K, Chevalier E, et al. The discovery of AZD9164, a novel muscarinic M3 antagonist. Bioorg Med Chem Lett. 2011;21(24):7440–7446. doi:10.1016/j.bmcl.2011.10.002
   PubMed Web of Science ®Google Scholar
• Bjermer L, Bengtsson T, Jorup C, et al. Local and systemic effects of inhaled AZD9164 compared with tiotropium in patients with COPD. Respir Med. 2013;107(1):84–90. doi:10.1016/j.rmed.2012.09.014
   PubMed Web of Science ®Google Scholar
• Mete A, Bowers K, Bull RJ, et al. The design of a novel series of muscarinic receptor antagonists leading to AZD8683, a potential inhaled treatment for COPD. Bioorg Med Chem Lett. 2013;23(23):6248–6253. doi:10.1016/j.bmcl.2013.09.092
   PubMed Web of Science ®Google Scholar
• Kobayashi F, Yageta Y, Segawa M, et al. Effects of imidafenacin (KRP-197/ONO-8025), a new anti-cholinergic agent, on muscarinic acetylcholine receptors. Arzneimittelforschung. 2011;57(02):92–100. doi:10.1055/s-0031-1296589
   Google Scholar
• Machida K, Kawayama T, Kinoshita M, et al. Imidafenacin, an orally active muscarinic receptor antagonist, improves pulmonary function in patients with chronic obstructive pulmonary disease: a multicenter, randomized, double-blind, placebo-controlled 3×3 crossover phase II trial. Int J Chron Obstruct Pulmon Dis. 2019;14:2175–2184. doi:10.2147/COPD.S223002
   Web of Science ®Google Scholar
• Oleson L, Turncliff R, Silverman B. ALKS 27 (trospium inhalation powder) improves lung function following single administration in subjects with COPD (abstract). Am J Respir Crit Care Med. 2010;181:A4457.
   Google Scholar
• Singh D, Fuhr R, Jimenez L, et al. A randomized trial of dual-acting bronchodilator AZD8871 for chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2019;199(10):1282–1284. doi:10.1164/rccm.201812-2345LE
   PubMed Web of Science ®Google Scholar
• Hegde SS, Hughes AD, Chen Y, et al. Pharmacologic characterization of GSK-961081 (TD-5959), a first-in-class inhaled bifunctional bronchodilator possessing muscarinic receptor antagonist and β2-adrenoceptor agonist properties. J Pharmacol Exp Ther. 2014;351(1):190–199. doi:10.1124/jpet.114.216861
   Web of Science ®Google Scholar
• Ambery C, Young G, Fuller T, et al. Pharmacokinetics, excretion, and mass balance of [14C]-batefenterol following a single microtracer intravenous dose (concomitant to an inhaled dose) or oral dose of batefenterol in healthy men. Clin Pharmacol Drug Dev. 2018;7(8):901–910. doi:10.1002/cpdd.616
   Web of Science ®Google Scholar
• Wielders PLML, Ludwig-Sengpiel A, Locantore N, et al. A new class of bronchodilator improves lung function in COPD: a trial with GSK961081. Eur Respir J. 2013;42(4):972–981. doi:10.1183/09031936.00165712
   PubMed Web of Science ®Google Scholar
• Ambery CL, Wielders P, Ludwig-Sengpiel A, et al. Population pharmacokinetics and pharmacodynamics of GSK961081 (batefenterol), a muscarinic antagonist and β2-agonist, in moderate-to-severe COPD patients: substudy of a randomized trial. Drugs R D. 2015;15(3):281–291. doi:10.1007/s40268-015-0104-x
   Google Scholar
• Bateman ED, Kornmann O, Ambery C, et al. Pharmacodynamics of GSK961081, a bi-functional molecule, in patients with COPD. Pulm Pharmacol Ther. 2013;26(5):581–587. doi:10.1016/j.pupt.2013.03.015
   PubMed Web of Science ®Google Scholar
• Norris V, Ambery C. Bronchodilation and safety of supratherapeutic doses of salbutamol or ipratropium bromide added to single dose GSK961081 in patients with moderate to severe COPD. Pulm Pharmacol Ther. 2013;26(5):574–580. doi:10.1016/j.pupt.2013.03.009
   PubMed Web of Science ®Google Scholar
• Crim C, Watkins ML, Bateman ED, et al. Randomized dose-finding study of batefenterol via dry powder inhaler in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2015;15:615–629. doi:10.2147/COPD.S190603
   Web of Science ®Google Scholar
• Ambery C, Young G, Fuller T, et al. Open-label, crossover study to determine the pharmacokinetics of fluticasone furoate and batefenterol when administered alone, in combination, or concurrently. Clin Pharmacol Drug Dev. 2019;8(2):188–197. doi:10.1002/cpdd.603
   Web of Science ®Google Scholar
• Norris V, Ambery C, Riley T. Pharmacokinetics and pharmacodynamics of GSK961081, a novel inhaled muscarinic antagonist β 2 -agonist, and fluticasone propionate administered alone, concurrently and as a combination blend formulation in healthy volunteers: clinical pharmacology in drug development. Clin Pharmacol Drug Dev. 2014;3:305–313.
   Web of Science ®Google Scholar
• Ambery C, Riddell K, Daley-Yates P. Open-label, randomized, 6-way crossover, single-dose study to determine the pharmacokinetics of batefenterol (GSK961081) and fluticasone furoate when administered alone or in combination. Clin Pharmacol Drug Dev. 2016;5(5):399–407. doi:10.1002/cpdd.274
   Web of Science ®Google Scholar
• Crim C, Gotfried M, Spangenthal S, et al. A randomized, controlled, repeat-dose study of batefenterol/fluticasone furoate compared with placebo in the treatment of COPD. BMC Pulm Med. 2020;20(1):119. doi:10.1186/s12890-020-1153-7
   PubMed Web of Science ®Google Scholar
• Norman P. Novel dihydroquinoline-based MABAs; clues to the identity of LAS-190792: evaluation of WO20111411802. Expert Opin Ther Pat. 2012;22(2):185–192. doi:10.1517/13543776.2012.655270
   Web of Science ®Google Scholar
• Aparici M, Carcasona C, Ramos I, et al. Pharmacological preclinical characterization of LAS190792, a novel inhaled bifunctional muscarinic receptor antagonist /β 2 -adrenoceptor agonist (MABA) molecule. Pulm Pharmacol Ther. 2017;46:1–10. doi:10.1016/j.pupt.2017.07.003
   PubMed Web of Science ®Google Scholar
• Astbury C, Pujol H, Massana È, et al. A Randomized Placebo Controlled Trial of AZD8999 (LAS190792) a Novel Dual Acting Bronchodilator in Asthmatics. Airway Pharmacology and Treatment. European Respiratory Society; 2017:OA4406. Available from: http://erj.ersjournals.com/lookup/doi/10.1183/1393003.congress-2017.OA4406. Accessed November 25, 2020.
   Google Scholar
• Milara J, Contreras S, de Diego A, et al. In vitro anti-inflammatory effects of AZD8999, a novel bifunctional muscarinic acetylcholine receptor antagonist /β2-adrenoceptor agonist (MABA) compound in neutrophils from COPD patients. PLoS One. 2019;14(1):e0210188. doi:10.1371/journal.pone.0210188
   PubMed Web of Science ®Google Scholar
• Aparici M, Carcasona C, Ramos I, et al. Pharmacological profile of AZD8871 (LAS191351), a novel inhaled dual M3 receptor antagonist/β2-adrenoceptor agonist molecule with long-lasting effects and favorable safety profile. J Pharmacol Exp Ther. 2019;370:127–136. doi:10.1124/jpet.118.255620
   PubMed Web of Science ®Google Scholar
• Calzetta L, Ritondo BL, Matera MG, et al. Investigational treatments in phase I and II clinical trials: a systematic review in chronic obstructive pulmonary disease (COPD). Expert Opin Investig Drugs. 2020;1–16.
   Web of Science ®Google Scholar
• Jimenez L, Astbury C, Seoane B, et al. A Randomized Placebo Controlled Trial of AZD8871 a Novel Dual Acting Bronchodilator in Asthmatics. Airway Pharmacology and Treatment. European Respiratory Society; 2017:PA1811. Available from: http://erj.ersjournals.com/lookup/doi/10.1183/1393003.congress-2017.PA1811. Accessed November 25, 2020.
   Google Scholar
• Norman P. Evaluation of WO-2012085582 and WO-2012085583 two identified MABAs: backups to AZD-2115? Expert Opin Ther Pat. 2012;22(11):1377–1383. doi:10.1517/13543776.2012.718761
   PubMed Web of Science ®Google Scholar
• Cselényi Z, Jucaite A, Kristensson C, et al. Quantification and reliability of [11C]VC - 002 binding to muscarinic acetylcholine receptors in the human lung — a test-retest PET study in control subjects. EJNMMI Res. 2020;10(1):59. doi:10.1186/s13550-020-00634-0
   PubMed Web of Science ®Google Scholar
• Carnini C, Cesari N, Rudolph K, et al. Bronchoprotective Activity and Safety Evaluation of the Novel Antimuscarinic/Β2 Agonist (MABA) CHF6366 in Dogs. Airway Pharmacology and Treatment. European Respiratory Society; 2017:PA1804. Available from: http://erj.ersjournals.com/lookup/doi/10.1183/1393003.congress-2017.PA1804. Accessed November 25, 2020.
   Google Scholar
• Miglietta D, Carnini C, Bassani F, et al. CHF6366: Characterisation of the Bronchoprotective Effect of a Novel MABA Compound in the Experimental Bronchospasm Model in Anaesthetised Guinea Pigs. Airway Pharmacology and Treatment. European Respiratory Society; 2017:OA4405. Available from: http://erj.ersjournals.com/lookup/doi/10.1183/1393003.congress-2017.OA4405. Accessed November 25, 2020.
   Google Scholar
• McNamara A, Steinfeld T, Pulido-Rios MT, et al. Preclinical efficacy of THRX-200495, a dual pharmacology muscarinic receptor antagonist and β(2)-adrenoceptor agonist (MABA). Pulm Pharmacol Ther. 2012;25:357–363. doi:10.1016/j.pupt.2012.06.007
   PubMed Web of Science ®Google Scholar
• Barnes PJ, Bonini S, Seeger W, et al. Barriers to new drug development in respiratory disease. Eur Respir J. 2015;45(5):1197–1207. doi:10.1183/09031936.00007915
   PubMed Web of Science ®Google Scholar
• Cazzola M, Calzetta L, Ora J, et al. Searching for the synergistic effect between aclidinium and formoterol: from bench to bedside. Respir Med. 2015;109(10):1305–1311. doi:10.1016/j.rmed.2015.08.005
   PubMed Web of Science ®Google Scholar
• Ismaila AS, Huisman EL, Punekar YS, et al. Comparative efficacy of long-acting muscarinic antagonist monotherapies in COPD: a systematic review and network meta-analysis. Int J Chron Obstruct Pulmon Dis. 2015;10:2495–2517. doi:10.2147/COPD.S92412
   PubMed Web of Science ®Google Scholar
• Cazzola M, Lopez-Campos J-L, Puente-Maestu L. The MABA approach: a new option to improve bronchodilator therapy. Eur Respir J. 2013;42(4):885–888. doi:10.1183/09031936.00067013
   PubMed Web of Science ®Google Scholar